Dual Targeted Lentiviral Transduced Anti-CD20/Anti-CD19 (LV20.19) CAR T cells for Relapsed, Refractory CLL

Key Points

• CAR T cells demonstrated significant activity against malignant B cells in relapsed and refractory CLL cases, indicating promising treatment outcomes.
• The study highlighted the use of dual targeting—anti-CD20 and anti-CD19—resulting in a more effective response to therapy in specific CLL populations.
• Lentiviral transduction was employed to create the CAR T cells, which expanded and persisted longer in circulation, enhancing their anti-tumor capacity.
• The findings suggest that dual targeting may improve treatment responses but require validation in larger cohorts for broader applicability.